Prostate cancer prevention: Concepts and clinical recommendations

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 4, 2010, Pages 300-306

  Silberstein, J L ^a   Parsons, J K ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

5 ARI; chemoprevention; PCPT; prevention; REDUCE

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN RECEPTOR; ANDROSTANOLONE; ASCORBIC ACID; BICALUTAMIDE; DUTASTERIDE; ESTROGEN RECEPTOR ALPHA; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SELENOMETHIONINE; STEROID 5ALPHA REDUCTASE INHIBITOR; TOREMIFENE;

BREAST CANCER; CANCER GROWTH; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIGITAL RECTAL EXAMINATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; ERECTILE DYSFUNCTION; GYNECOMASTIA; HEALTH FOOD; HIGH RISK PATIENT; HUMAN; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVIEW; RISK REDUCTION; THROMBOEMBOLISM; VEGETABLE;

ALGORITHMS; CARCINOMA; CHEMOPREVENTION; CONCEPT FORMATION; HEALTH PLANNING GUIDELINES; HUMANS; MALE; PRIMARY PREVENTION; PROSTATIC NEOPLASMS; TERTIARY PREVENTION;

EID: 78649325740     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.18     Document Type: Review

References (57)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Saigal CS, Litwin MS. The economic costs of early stage prostate cancer. Pharmacoeconomics 2002; 20: 869-878.
3. Schroeck FR, Krupski TL, Sun L, Albala DM, Price MM, Polascik TJ et al. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol 2008; 54: 785-793.
4. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 2007; 177: 2151-2156; discussion 2156.
5. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
6. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 366-381.
7. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10: 501-507.
8. Singer EA, Palapattu GS, van Wijngaarden E. Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey. Cancer 2008; 113: 2053-2057.
9. Murtola TJ, Visakorpi T, Lahtela J, Syvala H, Tammela T. Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol 2008; 5: 376-387.
10. Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 2008; 53: 244-252.
11. Rittmaster RS, Manning AP, Wright AS, Thomas LN, Whitefield S, Norman RW et al. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology 1995; 136: 741-748.
12. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
13. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99: 1375-1383.
14. Moinpour CM, Darke AK, Donaldson GW, Thompson Jr IM, Langley C, Ankerst DP et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99: 1025-1035.
15. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 2009; 27: 1502-1516.
16. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
17. Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P et al. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene 2005; 24: 5868-5877.
18. Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y et al. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 2006; 66: 1070-1075.
19. Etminan M, FitzGerald JM, Gleave M, Chambers K. Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Control 2005; 16: 1125-1131.
20. Cheung E, Wadhera P, Dorff T, Pinski J. Diet and prostate cancer risk reduction. Expert Rev Anticancer Ther 2008; 8: 43-50.
21. Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM et al. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Prostate 2007; 67: 582-590.
22. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90: 440-446.
23. Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8: 893-899.
24. Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 2006; 98: 245-254.
25. Wright ME, Weinstein SJ, Lawson KA, Albanes D, Subar AF, Dixon LB et al. Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2007; 16: 1128-1135.
26. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009; 301: 52-62.
27. Mirvish SS. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett 1995; 93: 17-48.
28. Wu HC, Lu HF, Hung CF, Chung JG. Inhibition by vitamin C of DNA adduct formation and arylamine N-acetyltransferase activity in human bladder tumor cells. Urol Res 2000; 28: 235-240.
29. Klein EA. Chemoprevention strategies. Grand Rounds Urol 2009; 8 (Suppl 1): 2-5.
30. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-1202.
31. Zhu YS, Sun GH. 5alpha-reductase Isozymes in the prostate. J Med Sci 2005; 25: 1-12.
32. Titus MYL, Kawinski E, Kozyreva O, Mohler JL. Biochemical and pharmacological evidence for a third isozyme of steroid 5a-reductase in prostate cancer. J Urol 2007; 177 (Suppl): 90-91.
33. Iehle C, Radvanyi F, Gil Diez de Medina S, Ouafik LH, Gerard H, Chopin D et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999; 68: 189-195.
34. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005; 63: 231-239.
35. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003; 57: 134-139.
36. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179-2184.
37. Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2007; 10: 149-154.
38. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505-508.
39. Span PN, Voller MC, Smals AG, Sweep FG, Schalken JA, Feneley MR et al. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol 1999; 161: 332-337.
40. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 1999; 155: 641-647.
41. Weinstein MH, Epstein JI. Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. Hum Pathol 1993; 24: 624-629.
42. Gallo F, Chiono L, Gastaldi E, Venturino E, Giberti C. Prognostic significance of high-grade prostatic intraepithelial neoplasia (HGPIN): risk of prostatic cancer on repeat biopsies. Urology 2008; 72: 628-632.
43. Parsons JK, Partin AW. Clinical interpretation of prostate biopsy reports. Urology 2006; 67: 452-457.
44. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006; 175 (3 Pt 1): 820-834.
45. Dong F, Reuther AM, Magi-Galluzzi C, Zhou M, Kupelian PA, Klein EA. Pathologic stage migration has slowed in the late PSA era. Urology 2007; 70: 839-842.
46. Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 2007; 28: 763-769.
47. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80.
48. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.
49. Andriole G, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995; 45: 491-497.
50. Schroder FH, Bangma CH, Wolff JM, Alcaraz A, Montorsi F, Mongiat-Artus P et al. Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study. BJU Int 2009; 103: 590-596.
51. Sartor O, Gomella LG, Gagnier P, Melich K, Dann R. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Can J Urol 2009; 16: 4806-4812.
52. Silberstein J, Parsons JK. Current concepts in diet and prostate cancer. Aging Health 2008; 4: 495-505.
53. Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000; 92: 61-68.
54. Parsons JK, Newman V, Mohler JL, Pierce JP, Paskett E, Marshall J. The Men's Eating and Living (MEAL) study: a Cancer and Leukemia Group B pilot trial of dietary intervention for the treatment of prostate cancer. Urology 2008; 72: 633-637.
55. Parsons JK, Newman VA, Mohler JL, Pierce JP, Flatt S, Marshall J. Dietary modification in patients with prostate cancer on active surveillance: a randomized, multicentre feasibility study. BJU Int 2008; 101: 1227-1231.
56. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol Biomarkers Prev 2006; 15: 1485-1489.
57. Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 2005; 118: 850-857.